硬化性被嚢性腹膜炎(sclerosing encapsulating peritonitis, SEP)診断・治療方針(案)  1997年における改訂

書誌事項

タイトル別名
  • Scleosing encapsulating peritonitis(SEP) in patients on continous ambulatory peritoneal dialysis. Definition, diagnosis and treatment recommendations, 1997 update.
  • Definition, diagnosis and treatment recommendations, 1997 update
  • 1997年における改訂

抄録

Sclerosing encapsulating peritonitis (SEP) is one of the most serious complications of CAPD. To revise the definition, diagnosis and therapeutic strategy for sclerosing encapsulating peritonitis (SEP) in patients on CAPD proposed over the last 3 years, a consensus meeting on SEP was held on November 29, 1997 in Tokyo. We confirmed that SEP is defined as clinical entity demonstrating persistent, intermittent and/or recurrent clinical symptoms due to adhesive bowel obstruction in patients receiving peritoneal dialysis. This year, we made minor changes concerning the recommended treatment of SEP. The basic strategy for the treating SEP is sustained bowel rest. Long-term total parental nutrition (TPN) therapy is effective for treating SEP patients. It was reported that steroid pulse therapy was effective in 6 of 8 and corticosteroid administration was effective in 15 of 23 patients treated at 26 hospitals, although there were some reports of fatal outcomes. This therapeutic intervention as well as an immunosuppressive regimen should be evaluated in a large patient population.<br>We also proposed criteria for discontinuing CAPD to prevent the development of SEP in adult and pediatric patients. However, SEP showed heterogeneity among individual patients. Therefore, we proposed only a basic strategy for treating SEP in this revised version. Further study is needed in this area.

収録刊行物

被引用文献 (3)*注記

もっと見る

詳細情報 詳細情報について

  • CRID
    1390001204676132096
  • NII論文ID
    130003721477
  • DOI
    10.4009/jsdt.31.303
  • ISSN
    1883082X
    13403451
  • 本文言語コード
    ja
  • データソース種別
    • JaLC
    • Crossref
    • CiNii Articles
  • 抄録ライセンスフラグ
    使用不可

問題の指摘

ページトップへ